127 related articles for article (PubMed ID: 37096638)
1. Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma.
Natsuhara KH; Huang CY; Knoche J; Arora S; Chung A; Martin T; Wolf J; Wong SW; Shah N; Banerjee R
Leuk Lymphoma; 2023 Jun; 64(6):1186-1193. PubMed ID: 37096638
[TBL] [Abstract][Full Text] [Related]
2. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A; Kyle R; Merlini G; Miguel JS; Ludwig H; Hajek R; Palumbo A; Jagannath S; Blade J; Lonial S; Dimopoulos M; Comenzo R; Einsele H; Barlogie B; Anderson K; Gertz M; Harousseau JL; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Richardson P; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R; Rajkumar SV; Durie BG;
Leukemia; 2009 Feb; 23(2):215-24. PubMed ID: 19020545
[TBL] [Abstract][Full Text] [Related]
3. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
[TBL] [Abstract][Full Text] [Related]
4. Can urine studies be replaced by serum free light chains measurements to assign responses in multiple myeloma patients?
Cárdenas MC; Iñigo B; Ortega I; Palomar MA; Menéndez M; Plaza P; Martínez-Novillo M; Benavente C
Front Oncol; 2022; 12():1056293. PubMed ID: 36531081
[TBL] [Abstract][Full Text] [Related]
5. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma.
Wiedemann Á; Szita VR; Horváth R; Szederjesi A; Sebő A; Tóth AD; Masszi T; Varga G
Pathol Oncol Res; 2023; 29():1611171. PubMed ID: 37188125
[No Abstract] [Full Text] [Related]
6. Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.
Fouquet G; Snell KI; Guidez S; Schraen S; Boyle E; Renaud L; Desmier D; Machet A; Moya N; Systchenko T; Gruchet C; Decaux O; Arnulf B; Fohrer C; Richez V; Kolb B; Macro M; Karlin L; Royer B; Pegourie B; Hebraud B; Caillot D; Perrot A; Moreau P; Facon T; Avet-Loiseau H; Dejoie T; Hulin C; Harding S; Leleu X
Leuk Lymphoma; 2018 Mar; 59(3):583-589. PubMed ID: 28697637
[TBL] [Abstract][Full Text] [Related]
7. Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
Tacchetti P; Rocchi S; Zamagni E; Barbato S; Rizzello I; De Cicco G; Pantani L; Mancuso K; Fusco A; Dozza L; Ursi M; Favero E; Terragna C; Testoni N; Cavo M
Am J Hematol; 2022 Dec; 97(12):1607-1615. PubMed ID: 36198076
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
[TBL] [Abstract][Full Text] [Related]
9. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions.
Khoriaty R; Hussein MA; Faiman B; Kelly M; Kalaycio M; Baz R
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):E10-3. PubMed ID: 20223721
[TBL] [Abstract][Full Text] [Related]
10. Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics.
Rifkin RM; Abonour R; Terebelo H; Shah JJ; Gasparetto C; Hardin J; Srinivasan S; Ricafort R; Nagarwala Y; Durie BG
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):368-76. PubMed ID: 25617035
[TBL] [Abstract][Full Text] [Related]
11. Quantification by Ultrafiltration and Immunofixation Electrophoresis Testing for Monoclonal Serum Free Light Chains.
Singh G; Bollag R
Lab Med; 2020 Nov; 51(6):592-600. PubMed ID: 32285117
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.
Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M
Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783
[TBL] [Abstract][Full Text] [Related]
13. Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines.
Fahmawi S; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy JD; Zhan F; van Rhee F; Al Hadidi S
J Cancer Policy; 2023 Sep; 37():100433. PubMed ID: 37468042
[TBL] [Abstract][Full Text] [Related]
14. Appraisal of immunoglobulin free light chain as a marker of response.
Dispenzieri A; Zhang L; Katzmann JA; Snyder M; Blood E; Degoey R; Henderson K; Kyle RA; Oken MM; Bradwell AR; Greipp PR
Blood; 2008 May; 111(10):4908-15. PubMed ID: 18364469
[TBL] [Abstract][Full Text] [Related]
15. Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma.
Narita K; Kobayashi H; Abe Y; Kitadate H; Takeuchi M; Matsue K
Int J Hematol; 2018 Oct; 108(4):371-374. PubMed ID: 29978432
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the screening value of serum light chain ratio, β2 microglobulin, lactic dehydrogenase and immunoglobulin in patients with multiple myeloma using ROC curves.
Ying L; Zhang X; Lu N; Zhao L; Nie Y; Wang G; Chen S; Xu L
PLoS One; 2023; 18(2):e0281743. PubMed ID: 36795719
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.
Caillon H; Avet-Loiseau H; Attal M; Moreau P; Decaux O; Dejoie T
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e228-e237. PubMed ID: 30799237
[TBL] [Abstract][Full Text] [Related]
18. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
[TBL] [Abstract][Full Text] [Related]
19. oligoclonal bands in patients with multiple myeloma: its emergence per se could not be translated to improved survival.
Fujisawa M; Seike K; Fukumoto K; Suehara Y; Fukaya M; Sugihara H; Takeuchi M; Matsue K
Cancer Sci; 2014 Nov; 105(11):1442-6. PubMed ID: 25182124
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
